Idaho Hematology and Breast Cancer Conference

Boise, ID US
February 9, 2024 to February 10, 2024

The Idaho Hematology and Breast Cancer Conference, is a CME-accredited, in-person hematology oncology conference featuring leading hematology and breast cancer experts. Expert faculty will place key abstract findings from the 65th ASH Annual Meeting (ASH2023) and the San Antonio Breast Cancer Symposium (SABCS2023) into clinical context and discuss how the results may change the current standards of care for patients with benign and malignant hematologic disorders and breast cancer. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

This conference allows attendees an opportunity to discuss current research and advances in the field of hematologic disorders and breast cancer with colleagues and key opinion leaders. The goals of this conference are to review and critically assess the results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients. 

ORGANIZING COMMITTEE 

Course Director:

Binay Shah, MD, MHA Binaytara Foundation

Conference Chair: 

Andrew Scott Pierson, MD- Saint Alphonsus Cancer Institute

HOTEL RESERVATION INFORMATION 

A limited number of guestrooms have been booked at the Grove Hotel for attendees, exhibitors, and faculty of this meeting. Please use the link below to book your hotel room at a discounted rate of $199/night. Please book by Monday, January 8, 2024 to receive the discounted guestroom rate.

Booking link: https://reservations.travelclick.com/76224?groupID=4143982

Attendees and exhibitors can also call the hotel at 1-208-489-2222 or 1-888-961-5000 to book the rooms.

Target Audience

  • Hematologists, Oncologists
  • Surgeons
  • Radiation Oncologists
  • Physician Assistants/Nurse Practitioners
  • Pharmacists
  • Nurses

 

Learning Objectives

  1. Review data presented at the ASH2023 and SABCS2023 & discuss their applications in clinical settings.    
  2. Choose new therapeutic options for treating benign and malignant hematologic disorders & breast cancer, understanding appropriate indications and contraindications to these therapeutic approaches.
  3. Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care in hematology and breast cancer.
  4. Integrate evolving diagnostic, prognostic, and therapeutic approaches to managing hematologic disorders and breast cancer patients.
  5. Individualize management of patients based on emerging data from clinical trials and evolving expert guidelines.

GLOBAL ONCOLOGY PROJECT

To learn more about our ongoing project building a 200-bed cancer hospital in Nepal:

Course summary
Available credit: 
  • 8.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.25 Contact Hours.
Course opens: 
11/16/2023
Course expires: 
05/17/2024
Event starts: 
02/09/2024 - 4:00pm PST
Event ends: 
02/10/2024 - 4:00pm PST
Cost:
$200.00

DAY 1 - FEBRUARY 9th, 2024

All times are listed in Mountain Standard Time (MST)

04:00 PM – 04:45 PM: Registration/Networking & Exhibits


04:45 PM – 05:00 PM: Opening remarks


05:00 PM – 06:30 PM: Session 1 – Case-based discussion

Moderator: Andrew Scott Pierson, MD

Case 1 – Bleeding disorder- Prakash Vishnu, MD, FACP

Case 2 – Smoldering myeloma- Aaron Goodman, MD

Case 3 – ITP- Andrew Scott Pierson, MD

Case 4 – Bone marrow failure- Anuhya Kommalapati, MD


06:30 PM – 07:15 PM: Networking/reception & Exhibits


DAY 2 - FEBRUARY 10th, 2024

07:00 AM – 08:00 AM: Breakfast & Exhibits

08:00 AM- 08:15 AM: Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD


08:15 AM – 09:45 AM: Session 2

Moderator: Travis Williams, DO

08:15 AM – 08:40 AM: MDS/Acute Leukemia- Roland Walter, MD, PhD, MS

08:40 AM – 09:05 AM: Myeloproliferative neoplasms and CML- Tsewang Tashi, MD

09:05 AM – 09:30 AM: Cellular therapy in hematologic malignancies – recent updates- Swathi Namburi, MD

09:30 AM – 09:45 AM: Q & A


09:45 AM – 10:00 AM:  Break & exhibits


10:00 AM – 11:45 AM: Session 3

Moderator: Clinton Morgan, MD

10:00 AM – 10:25 AM: Lymphoma- Ryan Lynch, MD

10:25 AM – 10:50 AM: Chronic lymphocytic leukemia-  Alexey Danilov, MD, PHD

10:50 AM – 11:15 AM: Multiple myeloma- Rebecca Silbermann, MD, MMS

11:15 AM – 11:45 AM: Q & A


11:45 AM - 12:45 PM: Lunch & exhibits

Product Theater Sponsored by Novartis *Non CME Activity* in Ivy Room

Topic: Addressing the Needs of Patients Across the HR+/HER2- Landscape: The Role of KISQALI (Ribociclib)

Speaker: Irina Kreyman, Director P2P Breast and Women’s Cancer at Novartis


12:45 PM - 02:30 PM: Session 4

Moderator: Stephanie Hodson, MD

12:45 PM - 01:10 PM: Hormone receptor positive breast cancer- Mei Wei, MD

01:10 PM - 01:35 PM: HER2 positive breast cancer- David Page, MD

01:35 PM - 02:00 PM: Triple negative and HER2 low breast cancer- Christos Vaklavas, MD

02:00 PM – 02:30 PM: Q & A


02:30 PM – 02:45 PM: Break & exhibits


02:45 PM – 04:30 PM: Session 5

Moderator: Elizabeth Prier, MD FACS

02:45 PM – 03:10 PM: Radiotherapy – best breast practice- Camille Berriochoa, MD

03:10 PM – 03:35 PM: Updates in surgical approach – best breast practice- Kshama Jaiswal, MD, FACS

03:35 PM – 03:50 PM: Q & A

03:50 PM – 04:30 PM: Case-based discussion

Case 1 – DCIS- Gliceida Galarza Fortuna, MD

Case 2 – Inflammatory breast cancer- Wendy Wang, MD, PhD

Case 3 – Early Stage breast cancer- Laura Miotke, MD


04:30 PM – 04:35 PM: Adjourn

The Grove Hotel
245 S Capitol Blvd
Boise, ID 83702
United States

Booking link: https://reservations.travelclick.com/76224?groupID=4143982

Book your rooms by January 8th to receive a discounted rate of $199 at night. 

Attendees and exhibitors can also call the hotel at 1-208-489-2222 or 1-888-961-5000 to book the rooms.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Andrew Pierson, MD

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Camille Berriochoa

has no relevant financial relationships to disclose at this time.

Alexey Danilov, MD, PhD

has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Grant Or Contract) with MEI;.
has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Lilly;.
has a financial relationship (Grant Or Contract) with Nurix;.

Kshama Jaiswal

has no relevant financial relationships to disclose at this time.

Ryan Lynch

has a financial relationship (Grant Or Contract) with RAPT;.
has a financial relationship (Grant Or Contract) with SeaGen;.
has a financial relationship (Grant Or Contract) with TG Therapeutics;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Grant Or Contract) with Cyteir;.
has a financial relationship (Other) with Cancer Study Group;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Other) with Seagen;.

Swathi Namburi, MD

has no relevant financial relationships to disclose at this time.

David Page, MD

has a financial relationship (Professional Services) with Biotheranostics;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Independent contractor) with Sanford Burnham Presbys;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Independent contractor) with Brooklyn Immunotherapeutics;.
has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Independent contractor) with Clinical Care Options;.
has a financial relationship (Grant Or Contract) with WindMIL;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with NGM Bio;.
has a financial relationship (Independent contractor) with Astrazeneca/D-S;.
has a financial relationship (Grant Or Contract) with Brooklyn Immunotherapeutics;.
has a financial relationship (Independent contractor) with Oncocyte;.
has a financial relationship (Independent contractor) with Lilly;.

Rebecca Silbermann, MD, MMS

has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Grant Or Contract) with Sanofi-Aventis;.
has a financial relationship (Independent contractor) with Janssen;.

Tsewang Tashi

has a financial relationship (Professional Services) with CTI Biopharma;.
has a financial relationship (Professional Services) with PharmaEssentia;.
has a financial relationship (Professional Services) with Cogent Biosciences;.
has a financial relationship (Professional Services) with Blueprint Medicines;.

Christos Vaklavas, M.D., Associate Professor

has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Financial Support) with H3 Biomedicine;.
has a financial relationship (Professional Services) with Guidepoint;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Financial Support) with SeaGen;.
has a financial relationship (Employment) with Flatiron;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Financial Support) with Pfizer;.
has a financial relationship (Financial Support) with CytomX;.
has a financial relationship (Professional Services) with SeaGen;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Financial Support) with AstraZeneca;.

Roland Walter, MD PhD MS

has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Grant Or Contract) with ImmunoGen;.
has a financial relationship (Grant Or Contract) with Celgene;.
has a financial relationship (Stock Options) with Amphivena;.
has a financial relationship (Grant Or Contract) with Pfizer;.

Mei Wei, MD

has a financial relationship (Other) with Gilead Science;.
Case Presenter(s)

Gliceida Galarza Fortuna

has no relevant financial relationships to disclose at this time.

Aaron Goodman, MD

has a financial relationship (Professional Services) with Seattle Genetics;.

Anuhya Kommalapati, MD

has no relevant financial relationships to disclose at this time.

Laura Miotke

has no relevant financial relationships to disclose at this time.

Prakash Vishnu, MD, FACP

has no relevant financial relationships to disclose at this time.

Xiaowen Wang, MD, PhD

has no relevant financial relationships to disclose at this time.
Moderator(s)

Stephanie Hodson, MD, FACP

has a financial relationship (Independent contractor) with PRIME;.
has a financial relationship (Independent contractor) with PRIME;.

Clinton Morgan

has no relevant financial relationships to disclose at this time.

Elizabeth Prier, MD

has no relevant financial relationships to disclose at this time.

Travis Williams

has no relevant financial relationships to disclose at this time.

Available Credit

  • 8.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.25 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$200.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.